8-K current report · filed Oct 15, 2026

RECURSION PHARMACEUTICALS, INC. (RXRX) 8-K Current Report: October 15, 2026

Item 1.01Item 2.02Item 8.01Item EX-99.1Item EX-99.2Item EX-99.4Item 7.01RXRX overview

Short answer

RECURSION PHARMACEUTICALS, INC. (RXRX) filed an 8-K current report with the SEC on October 15, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.4 (Exhibit EX-99.4), Item 7.01 (Regulation FD Disclosure). Equity offering: 61.54 million Class A shares at $3.25 per share.

RECURSION PHARMACEUTICALS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Equity offering: 61.54 million Class A shares at $3.25 per share
  • Gross proceeds approximately $200 million before underwriting discounts and expenses
  • All shares issued by Recursion, creating shareholder dilution
  • Closing expected October 16, 2026, subject to customary conditions
  • Executive officers, directors and related entities subject to 45-day lock-ups with exceptions

Item 2.02 · Results of Operations and Financial Condition

  • Preliminary September 30 cash, equivalents and restricted cash: approximately $561 million
  • $86 million net proceeds from selling 23,696,330 Class A shares through the ATM program
  • Expected funding runway extended into 2029 for operating expenses and capital expenditures
  • Preliminary figures remain subject to closing adjustments and quarterly review, creating potential revision risk

Item 7.01 · Regulation FD Disclosure

  • Sanofi optioned a Recursion development candidate, signaling potential partnership validation and future deal economics
  • General corporate update released, with material operating details in Exhibit 99.2
  • Updated corporate presentation provides refreshed pipeline and strategic positioning in Exhibit 99.3

Item 8.01 · Other Events

  • Sanofi optioned the first collaboration candidate, triggering a $10M milestone and bringing cumulative upfront and milestone payments to $144M
  • Recursion remains eligible for over $300M in additional program milestones plus low-double-digit royalties, supporting non-dilutive partnership economics
  • REC-4881 reduced total polyp burden 47% median at week 13, with 85% remaining below baseline after 12 weeks off treatment
  • REC-1245 showed 91.7% disease control at eight weeks in 45mg or 65mg starters, but 65mg exceeded the maximum tolerated dose
  • Recursion selected 45mg daily for REC-1245 expansion cohorts, with preliminary endometrial cancer data expected in the second half of 2027

Item EX-99.1 · Exhibit EX-99.1

  • Sanofi optioned Recursion’s first collaboration development candidate, validating platform output and moving the program toward clinical development
  • $10M milestone payable in Q3 2026, bringing cumulative Sanofi upfront and milestone payments to $144M
  • Recursion eligible for over $300M additional program milestones plus low double-digit net-sales royalties
  • Sanofi funds and leads development, eliminating Recursion’s operational obligations and making future payments profit-bearing
  • Phase 1 trial planned for 2027, with clinical, regulatory and commercialization risks remaining ahead

Item EX-99.2 · Exhibit EX-99.2

  • $200M oversubscribed equity offering extends expected cash runway into 2029, but increases share-count dilution risk
  • REC-4881 delivered 47% median total polyp reduction after 12 weeks, with 85% remaining below baseline after treatment cessation
  • Upper GI results strengthened the FAP case: 55% median reduction, 92% response rate, and two patients achieving at least 98% reduction
  • REC-4881 registrational trial targeted for 2H 2027, pending FDA discussions, leaving regulatory pathway and timing unresolved
  • Sanofi option triggered a $10M milestone, bringing collaboration payments to $144M, with over $300M potential additional milestones plus low-double-digit royalties

Item EX-99.4 · Exhibit EX-99.4

  • $200 million gross equity raise, funding Recursion’s clinical pipeline and operations before underwriting costs
  • 61.54 million Class A shares priced at $3.25, creating material dilution for existing shareholders
  • Offering expected to close October 16, 2026, subject to customary conditions
  • Participation from Janus Henderson, Invus, Longaeva Partners, ARK Invest, and other institutional healthcare investors
  • Registered under Recursion’s effective Form S-3 shelf, indicating established access to public capital markets

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other RECURSION PHARMACEUTICALS, INC. 8-K filings

Get the next RXRX 8-K as it lands

Follow RXRX for push alerts, or ask the research agent what this filing means.